PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Studies have shown that some drugs ameliorate lipid accumulation and inflammation in nonalcoholic fatty liver disease through the AMPK pathway, such as LB100 [48], Ursolic acid [49], Allyl isothiocyanate [50], Ginsenoside Rk3 [51] and Kangtaizhi Granule [52].